To determine whether highly avid, oligoclonal NY-ESO-1 specific CD8+ T cells recognizing NY-ESO-1 positive tumor cell lines could be consistently isolated from patients who might benefit from NY-ESO-1 targeted therapy, we focused on patients with synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) because these tumors homogenously express NY-ESO-1, often with high intensity [20,21]. This evidence concerns the gene CD8A and neoplasm.